A Multiple Treatment Comparison of Eleven Disease-Modifying Drugs Used for Multiple Sclerosis

Abstract

Our results showed that alemtuzumab can be considered as more effective and less costly than the other treatment alternatives. There is a substantial potential cost saving if more patients start on the more effective and less costly treatment alternatives.